Technical Analysis for TGTX - TG Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
TGTX closed down 0.68 percent on Wednesday, November 22, 2017, on 1.63 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|Weak or Absent||Down||Down||Down|
|See historical TGTX trend table...|
|Date||Alert Name||Type||% Chg|
|Nov 22||NR7||Range Contraction||0.00%|
|Nov 22||Narrow Range Bar||Range Contraction||0.00%|
|Nov 22||Stochastic Reached Oversold||Other||0.00%|
|Nov 22||Lower Bollinger Band Walk||Other||0.00%|
|Nov 16||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||-11.45%|
|Nov 15||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||-13.02%|
|Nov 14||Stochastic Reached Overbought||Other||-15.03%|
|Nov 14||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||-15.03%|
|Nov 13||Death Cross||Bearish||-10.91%|
|Nov 13||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||-10.91%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more TGTX news...
|52 Week High||15.35|
|52 Week Low||4.1|
|200-Day Moving Average||10.4448|
|50-Day Moving Average||9.7073|
|20-Day Moving Average||7.9845|
|10-Day Moving Average||8.055|
|Average True Range||0.5238|
|Chandelier Exit (Long, 3 ATRs )||7.3786|
|Chandelier Exit (Short, 3 ATRs )||8.8214|
|Upper Bollinger Band||8.6896|
|Lower Bollinger Band||7.2794|
|Percent B (%b)||0.05|
|MACD Signal Line||-0.5474|
|Market Cap||457.98 Million|
|Num Shares||62.3 Million|
|Price-to-Earnings (P/E) Ratio||-3.77|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||7.73|
|Resistance 3 (R3)||7.73||7.62||7.66|
|Resistance 2 (R2)||7.62||7.52||7.61||7.64|
|Resistance 1 (R1)||7.48||7.46||7.43||7.48||7.62|
|Support 1 (S1)||7.23||7.27||7.18||7.23||7.08|
|Support 2 (S2)||7.12||7.21||7.11||7.06|
|Support 3 (S3)||6.98||7.12||7.04|
|Support 4 (S4)||6.98|